FDA approved Zaynich (cefepime and zidebactam) on May 29, 2026 for complicated urinary tract infections caused by drug-resistant Gram-negative pathogens. ENHANCE-1 Phase 3 trial showed superiority to meropenem at test of cure. Here is how it works and who benefits.